In a webinar on September 23, 2020, FasterCures brought together Peter Marks, director of the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research, Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society, and John Doyle, vice president and global healthcare innovation lead of Pfizer, to discuss the opportunities and challenges of long-term follow-up data collection for cell and gene therapy.

Over the hour-long discussion, the panelists talked about the importance of helping patients understand the value of their data and the need to ensure harmonization in data collection efforts. The panelists agreed on the potential of custom long-term data platforms to help answer outstanding questions about cell and gene therapy. The development of these platforms would be facilitated by a neutral party, such as the FDA or a patient organization, and created with the input of a coalition of interested stakeholders.

Moderator

Esther Krofah
Executive Director, FasterCures

Speakers

Peter Marks
Director of the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research

Gwen Nichols
Chief Medical Officer of the Leukemia & Lymphoma Society

John Doyle
Vice President and Global Healthcare Innovation Lead of Pfizer